These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28934023)

  • 1. Biomarker enrichment considerations in oncology early development single-arm studies.
    Tian H; Liu K
    J Biopharm Stat; 2018; 28(2):282-291. PubMed ID: 28934023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II cancer clinical trials for biomarker-guided treatments.
    Jung SH
    J Biopharm Stat; 2018; 28(2):256-263. PubMed ID: 28902567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New designs for basket clinical trials in oncology.
    Simon R
    J Biopharm Stat; 2018; 28(2):245-255. PubMed ID: 28877003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.
    Scher HI; Nasso SF; Rubin EH; Simon R
    Clin Cancer Res; 2011 Nov; 17(21):6634-40. PubMed ID: 22046024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical considerations of designs for single-arm proof-of-concept oncology trial with time-to-event endpoint.
    Zhou H; Sun L; Wang M
    Contemp Clin Trials; 2023 Jun; 129():107200. PubMed ID: 37068588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive expansion of biomarker populations in phase 3 clinical trials.
    Chen C; Li XN; Li W; Beckman RA
    Contemp Clin Trials; 2018 Aug; 71():181-185. PubMed ID: 29981858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints.
    Sinha AK; Moye L; Piller LB; Yamal JM; Barcenas CH; Lin J; Davis BR
    Stat Med; 2019 Sep; 38(21):3985-3996. PubMed ID: 31184783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multistage adaptive biomarker-directed targeted design for randomized clinical trials.
    Gao Z; Roy A; Tan M
    Contemp Clin Trials; 2015 May; 42():119-31. PubMed ID: 25778672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker enrichment strategies: matching trial design to biomarker credentials.
    Freidlin B; Korn EL
    Nat Rev Clin Oncol; 2014 Feb; 11(2):81-90. PubMed ID: 24281059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
    Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
    Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
    Jiang W; Freidlin B; Simon R
    J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to special issue on biomarker-based clinical trial designs in oncology.
    Sargent DJ; Mandrekar S; Grothey A
    Chin Clin Oncol; 2015 Sep; 4(3):28. PubMed ID: 26408295
    [No Abstract]   [Full Text] [Related]  

  • 18. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
    Mistry P; Dunn JA; Marshall A
    BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.
    Michiels S; Potthoff RF; George SL
    Stat Med; 2011 Jun; 30(13):1502-18. PubMed ID: 21344471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.